Cargando…

Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery

BACKGROUND: Nanocarrier platforms have been indicated to have great potential in clinical practice to treat non-small cell lung cancer (NSCLC). Our previous Phase III clinical study revealed that polymeric micellar paclitaxel (Pm-Pac) is safe and efficacious in advanced NSCLC patients. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Jun, Lou, Yuqing, Zhang, Yanwei, Zhong, Runbo, Zhang, Wei, Zhang, Xueyan, Wang, Huimin, Chu, Tianqing, Han, Baohui, Zhong, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844231/ https://www.ncbi.nlm.nih.gov/pubmed/36660338 http://dx.doi.org/10.2147/IJN.S372961

Ejemplares similares

Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?
por: Lou, Yuqing, et al.
Publicado: (2020)

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update
por: Lu, Jun, et al.
Publicado: (2022)

Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma
por: Hu, Minjuan, et al.
Publicado: (2020)

CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients
por: Zhang, Yanwei, et al.
Publicado: (2020)

Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy
por: Shen, Yinchen, et al.
Publicado: (2020)

A pH-Sensitive Polymeric Micellar System Based on Chitosan Derivative for Efficient Delivery of Paclitaxel
por: Han, Yang, et al.
Publicado: (2021)

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
por: Zhang, Bo, et al.
Publicado: (2022)

A Chitosan-Based Micellar System as Nanocarrier For the Delivery of Paclitaxel
por: Han, Yang, et al.
Publicado: (2020)

Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy
por: Chu, Tianqing, et al.
Publicado: (2023)

Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells
por: Zhang, Xueyan, et al.
Publicado: (2018)

Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
por: Lou, Yuqing, et al.
Publicado: (2021)

Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
por: Lu, Jun, et al.
Publicado: (2022)

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
por: Xiong, Anning, et al.
Publicado: (2023)

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases
por: Qiao, Rong, et al.
Publicado: (2019)

Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases
por: Qiao, Rong, et al.
Publicado: (2017)

Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer
por: Chen, Dongfang, et al.
Publicado: (2020)

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
por: Chu, Tianqing, et al.
Publicado: (2022)

Polymeric Micellar Systems—A Special Emphasis on “Smart” Drug Delivery
por: Negut, Irina, et al.
Publicado: (2023)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Supramolecular micellar nanoaggregates based on a novel chitosan/vitamin E succinate copolymer for paclitaxel selective delivery
por: Lian, He, et al.
Publicado: (2011)

Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis
por: Katragadda, Usha, et al.
Publicado: (2013)

An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation
por: Nakamura, Iwao, et al.
Publicado: (2017)

Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
por: Xu, Jianlin, et al.
Publicado: (2016)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
por: Li, Changhui, et al.
Publicado: (2021)

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
por: Zheng, Liang, et al.
Publicado: (2023)

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2021)

Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals
por: Lou, Yuqing, et al.
Publicado: (2022)

MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma
por: Zhang, Yanwei, et al.
Publicado: (2016)

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527
por: Li, Changhui, et al.
Publicado: (2021)

Light-Responsive Polymeric Micellar Nanoparticles with Enhanced Formulation Stability
por: Kim, Kyoung Nan, et al.
Publicado: (2021)

Sodium cholate-enhanced polymeric micelle system for tumor-targeting delivery of paclitaxel
por: Zhang, Xiaomin, et al.
Publicado: (2017)

Wnt blockers inhibit the proliferation of lung cancer stem cells
por: Zhang, Xueyan, et al.
Publicado: (2015)

Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2019)

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
por: Xu, Jianlin, et al.
Publicado: (2016)

Self-Assembled Polymeric Micellar Nanoparticles as Nanocarriers for Poorly Soluble Anticancer Drug Ethaselen
por: Li, Xinru, et al.
Publicado: (2009)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

Modulation of Hypoxia-Induced Chemoresistance to Polymeric Micellar Cisplatin: The Effect of Ligand Modification of Micellar Carrier Versus Inhibition of the Mediators of Drug Resistance
por: Soleymani Abyaneh, Hoda, et al.
Publicado: (2018)

Development and Characterization of Lecithin-based Self-assembling Mixed Polymeric Micellar (saMPMs) Drug Delivery Systems for Curcumin
por: Chen, Ling-Chun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d6uspjrjjfdfim6vd9updeu24h